Cheaper Ozempic launching on 27 July 2026
Novo Nordisk is launching an authorised copy of Ozempic in South Africa on 27 July 2026 — the first authorised semaglutide copy registered by SAHPRA. It’s called Extensior. Unlike a…
19 news items
Novo Nordisk is launching an authorised copy of Ozempic in South Africa on 27 July 2026 — the first authorised semaglutide copy registered by SAHPRA. It’s called Extensior. Unlike a…
Pretoria compounding pharmacy iDexis, trading as Sentra Pharmacy, has applied for leave to appeal the High Court order that stopped it from manufacturing and selling compounded medicines containing semaglutide.
South Africa's medicines regulator says weight-loss injections are now the single biggest category in its investigations into illicit medicine sales. Criminal syndicates are exploiting demand for GLP-1 medicines by selling…
Generic and lower-cost semaglutide options from Sun Pharma and Novo Nordisk/Acino are entering the South African market just as regulators intensify enforcement against unregistered compounded products. Here is what it…
Durban-based Aspen Pharmacare has received regulatory approval from Health Canada to distribute Aspen-Semaglutide, a generic alternative to Novo Nordisk's Ozempic. South Africa will manufacture the multi-dose pens while a French…
South Africa’s health products regulator (SAHPRA) said on Tuesday, July 21, that it is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and…
Novo Nordisk is partnering with Swiss pharma company Acino to launch "Extensior" — a lower-cost version of Ozempic — in South Africa on 27 July 2026, available in 0.25mg, 0.5mg…
The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, effectively closing the last legal pathway for large-scale compounded GLP-1 production. The public comment period…
Novo Nordisk secured an interim order from the Gauteng High Court in June 2026 preventing iDexis from manufacturing and selling compounded semaglutide. iDexis is now appealing this order alongside related…
SAHPRA has approved Sun Pharma's generic semaglutide injection, a biosimilar equivalent of Ozempic, for adults with type 2 diabetes. South Africa is only the second market after India to receive…
Tirzepatide (Mounjaro), distributed by Aspen Pharmacare, has become the largest-selling pharmaceutical product in South Africa. Meanwhile, generic semaglutide is expected to become available in South Africa as early as 2027,…
Following regulatory pressure on compounded GLP-1s, Hims & Hers announced a collaboration with Novo Nordisk in March 2026, shifting its US weight loss business to focus on FDA-approved medications at…
Register free to read every article, receive our weekly digest and submit questions to our expert panel.
Already registered? Sign in here